Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Entegris Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Entegris Inc. May 6, 202695.7%
-
Entegris Inc. April 23, 202594.2%
-
Entegris Inc. April 24, 202490.6%
-
Entegris Inc. April 26, 202393.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 6, 2026 | Entegris Inc. | Grant or award | +1,412 | — | — |
| Feb 27, 2026 | AbbVie Inc. | Shares withheld for tax | −16,309 | $232.08 | $3,784,993 |
| Feb 18, 2026 | AbbVie Inc. | Grant or award | +17,041 | — | — |
| Feb 18, 2026 | AbbVie Inc. | Grant or award | +6,058 | — | — |
| Feb 18, 2026 | AbbVie Inc. | Grant or award | +7,074 | — | — |
| Feb 18, 2026 | AbbVie Inc. | Grant or award | +6,638 | — | — |
| Aug 12, 2025 | AbbVie Inc. | Option exercise | +42,370 | $54.86 | $2,324,418 |
| Aug 12, 2025 | AbbVie Inc. | Open-market sale | −42,370 | $198.42 | $8,407,055 |
| Apr 23, 2025 | Entegris Inc. | Grant or award | +2,897 | — | — |
| Feb 28, 2025 | AbbVie Inc. | Shares withheld for tax | −17,056 | $205.02 | $3,496,821 |
| Feb 13, 2025 | AbbVie Inc. | Grant or award | +17,986 | — | — |
| Feb 13, 2025 | AbbVie Inc. | Grant or award | +7,378 | — | — |
| Feb 13, 2025 | AbbVie Inc. | Grant or award | +6,060 | — | — |
| Feb 13, 2025 | AbbVie Inc. | Grant or award | +7,074 | — | — |
| Sep 24, 2024 | AbbVie Inc. | Gift | −25,630 | — | — |
Questions about Azita Saleki-Gerhardt
What boards is Azita Saleki-Gerhardt on?
Azita Saleki-Gerhardt sits on the board of Entegris Inc.
How long has Azita Saleki-Gerhardt served on boards?
Our records show at least 4 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.